| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2a data readout example | Phase 1/2a | — | Subscribe to access the data. | Gene Therapies | Infectious Diseases | ||
Phase 1/2a data readout example | Phase 1/2a | — | Subscribe to access the data. | Gene Therapies | Infectious Diseases | ||
Phase 1/2a data readout example | Phase 1/2a | — | Subscribe to access the data. | Gene Therapies | Infectious Diseases |
Recent Updates
Recently added Catalysts
Precision BioSciences, Inc.$8.76
-0.4 (-4.37%)
B 61Pipeline Score Undervalued Biotech · Commercial
Market Cap
186.55 M
EPS
-3.71
P/E Ratio
-
Value Trade
1.44 M
SEC Financials
Q1 2026Dilution Risk
Revenue
10.84 M
R&D Expenses
13.11 M
Operating CF
-11.94 M
Total Assets
143.89 M
Total Liabilities
67.79 M
Equity
76.10 M
D/E Ratio
12,345
-9.74 %
Week
-3.34 %
1 Month
87.79 %
3 Month
45.47 %
6 Month
-97.67 %
5 Year
-98.66 %
All Time
Cash Data
Cash Position
101.18 M
Monthly Burn
3.98 M
Runway
23.4 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
579.60 K
52 Week Range
3.53 - 8.82
% held by Insiders
11.23 %
% held by Institutions
62.58 %
Enterprise Value
113.83 M
Total Shares
25.81 M
Short %
9.47 %
Float Shares
24.26 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Precision BioSciences, Inc.
398Total events
7Upcoming
75Tier-1 (high impact)
2019 – 2026Coverage
Upcoming catalysts 7
2026-H2
T1Topline Readout
Initial data from Phase 1 trial of PBGENE-DMD expected in second half of 2026
TBD
T3Type C Meeting
Imugene scheduled Type C meeting with FDA to discuss pivotal study design for azer-cel
2026-H1
T1Topline Readout
iECURE expects to release additional data from OTC-HOPE trial in first half of 2026
2026-H1
T1Topline Readout
Additional clinical biomarker and biopsy data expected in first half of 2026
2026-H1
T2Enrollment Complete
Expected completion of dosing in Cohorts 3, 4, and 5 in first half of 2026
2026-H2
T2Oral Presentation
Preliminary Phase 1 azer-cel data in progressive MS expected in second half of 2026
Event history 391
May 27, 2026
◆Late-BreakerPBGENE-HBVPresentation
Late-breaking poster presentation of new clinical biopsy data at EASL Congress 2026
chronic hepatitis Bsource ↗
May 27, 2026
▲Oral PresentationPBGENE-HBVPresentation
Late-breaking clinical data from ELIMINATE-B study presented at EASL 2026
chronic hepatitis Bsource ↗
May 27, 2026
▲Full ResultsPBGENE-HBVClinical Data
Liver biopsy data showing 1-log reduction in cccDNA transcripts and polymerase inactivation
chronic hepatitis Bsource ↗
May 27, 2026
▲Biomarker DataPBGENE-HBVClinical Data
pgRNA loss in 100% of patients with detectable pgRNA at baseline
chronic hepatitis Bsource ↗
May 27, 2026
▲Safety Data UpdatePBGENE-HBVClinical Data
Safety data: no DLTs, manageable profile with mitigation protocol for hypotension
chronic hepatitis Bsource ↗
May 21, 2026
◆Late-BreakerPBGENE-HBVPresentation
Late-breaking PBGENE-HBV data from ELIMINATE-B trial presented at EASL 2026
chronic hepatitis Bsource ↗
May 21, 2026
◆Oral PresentationPBGENE-HBVPresentation
Investor webcast to discuss late-breaking PBGENE-HBV data from ELIMINATE-B trial
chronic hepatitis Bsource ↗
May 14, 2026
▲Preclinical PoCPBGENE-DMDPreclinical
New preclinical data presented at ASGCT 2026 supporting advancement of PBGENE-DMD into clinic
Duchenne muscular dystrophysource ↗
May 14, 2026
◆Oral PresentationPBGENE-DMDPresentation
Oral presentation of PBGENE-DMD preclinical data at ASGCT 2026
Duchenne muscular dystrophysource ↗
May 5, 2026
Apr 29, 2026
▲First Patient DosedPBGENE-DMDTrial
First clinical trial site activated and patient screening/enrollment opened for PBGENE-DMD in FUNCTION-DMD study
Duchenne muscular dystrophysource ↗
Apr 15, 2026
▲Trial InitiationTrial
Clinical trial application approved in two European countries for ELIMINATE-B trial
Hepatitis Bsource ↗
Drug Pipeline Intelligence
B61
Pipeline Score $1.1B
Pipeline ValueUndervalued
Valuation Signal39
Drugs Scored5.8x
rNPV / MCap Top 89%
Micro Cap (rank 101 of 911)
Percentile RankPrecision BioSciences, Inc. holds a solid B-grade pipeline (61/100), with $8.9B risk-adjusted pipeline value, led by PDI-192 in Atopic Dermatitis (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PDI-192 Small molecule | Atopic Dermatitis | Phase 2 | NCT01826461 | 33% | $1.4B | COMPLETED | 151 | - | - | Dec 1, 2013 | - | May 29, 2014 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PBGENE-HBV | chronic hepatitis B | — | 2026-05-27 | 1-log (10-fold) reduction in cccDNA-derived transcripts; 100% of patients with detectable pgRNA at baseline achieved pgRNA loss Read More | Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 Read More | |
PBGENE-HBV | chronic hepatitis B | — | 2026-05-27 | 1-log (10-fold) reduction in cccDNA-derived transcripts; 100% of patients with detectable pgRNA at baseline achieved pgRNA loss Read More | Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 Read More | |
PBGENE-HBV | chronic hepatitis B | — | 2026-05-27 | 1-log (10-fold) reduction in cccDNA-derived transcripts; 100% of patients with detectable pgRNA at baseline achieved pgRNA loss Read More | Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DTIL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
DTIL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
DTIL▲ +8.6%on this news
Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors
Precision BioSciences has been included in the Russell 2000® Index, which is expected to enhance its market visibility and attract institutional investors. This inclusion reflects the company's growth and stability in the biopharma sector. The move is anticipated to bolster investor confidence and expand the company's reach.
Read more →DTILFirst evidence of elimination and inactivation of cccDNA in liver biopsies collected from patients with chronic hepatitis B treated with PBGENE-HBV
The article discusses groundbreaking findings on the elimination and inactivation of cccDNA in liver biopsies from chronic hepatitis B patients treated with PBGENE-HBV. This evidence was presented at the European Association for the Study of the Liver (EASL) Conference, indicating a significant advancement in hepatitis B treatment. The results suggest potential for PBGENE-HBV as a viable therapeutic option.
Read more →DTILPrecision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
Precision BioSciences has announced new and late-breaking clinical data from the PBGENE-HBV study during the European Association for the Study of the Liver Congress 2026. The details of the data and its implications for HBV treatment were highlighted, although specifics were not provided in the announcement.
Read more →DTILPrecision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
Precision BioSciences is set to host an investor webcast to discuss the late-breaking data from the PBGENE-HBV trial presented at the European Association for the Study of the Liver Congress 2026. This event will provide insights into the findings and implications of the trial results for stakeholders. Further details about the webcast will be shared as the event approaches.
Read more →DTILPrecision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
Precision BioSciences has presented new preclinical data for PBGENE-DMD at the American Society of Gene & Cell Therapy 2026 Annual Meeting. This advancement supports the transition of the therapy into clinical trials. The presentation highlights the company's ongoing commitment to developing innovative gene therapies.
Read more →DTILPrecision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences has reported its financial results for the first quarter of 2026. The company also provided a business update, although specific details regarding performance or future plans were not disclosed in the article. The report appears to be standard for quarterly financial disclosures.
Read more →DTILPrecision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
Precision BioSciences, Inc. has announced it will report its financial results for the first quarter of 2026 on May 5, 2026. The company is known for its proprietary ARCUS gene editing platform, which aims to develop therapies for genetic and infectious diseases. This announcement comes as the company continues to work on its clinical stage candidates.
Read more →DTILPrecision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
Precision BioSciences has activated the first clinical trial site for its PBGENE-DMD treatment aimed at Duchenne muscular dystrophy (DMD). The Phase 1/2 FUNCTION-DMD study will evaluate the safety, tolerability, and efficacy of this novel gene editing therapy. Patient enrollment has commenced at Arkansas Children's Hospital, which is recognized for its specialized care in DMD.
Read more →DTILPrecision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
Precision BioSciences announced that new preclinical data from its PBGENE-DMD program will be presented at the ASGCT 2026 Annual Meeting. The data highlights the efficacy of PBGENE-DMD in early-juvenile mice, suggesting potential benefits for younger patients with Duchenne muscular dystrophy. The program aims to improve function in about 60% of DMD patients and has received FDA designations to expedite its development.
Read more →DTILPrecision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences has announced the approval of an inducement award of 7,094 restricted stock units (RSUs) to a new employee. This decision was made by the Compensation Committee of the Board of Directors on April 20, 2026. The company continues to utilize its ARCUS® platform for developing in vivo gene editing therapies.
Read more →DTIL▲ +6.3%on this newsshared move
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026
Precision BioSciences announced a late-breaking poster presentation for PBGENE-HBV at the EASL Congress 2026, showcasing new clinical biopsy data from the Phase 1 ELIMINATE-B trial. This trial evaluates PBGENE-HBV as a treatment for chronic hepatitis B, aiming to eliminate cccDNA, the root cause of the infection. The program has received Fast Track designation from the FDA, highlighting its potential as a curative therapy.
Read more →DTIL▲ +5.9%on this news
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
Precision BioSciences has received approval for its ELIMINATE-B trial in two European countries. This expansion allows for broader patient enrollment and enhances the trial's potential impact. The move signifies a positive step forward in their clinical research efforts.
Read more →DTILPrecision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference
Precision BioSciences is set to participate in the 25th Annual Needham Virtual Healthcare Conference. The event will provide a platform for the company to discuss its advancements and strategies in the biopharma sector. Further details regarding their presentation and participation have not been disclosed.
Read more →DTIL▲ +12.1%on this news· ran to +37% by day 3
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
Precision BioSciences has reported positive results from its fourth quarter and fiscal year 2025, highlighting the successful execution of the Phase 1 ELIMINATE-B trial for PBGENE-HBV. The trial has dosed 13 patients across the first five cohorts, demonstrating safety, tolerability, and promising antiviral activity. These findings were showcased in a Late Breaker presentation at AASLD, The Liver Meeting.
Read more →DTIL▲ +12.1%on this news· ran to +37% by day 3shared move
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update - PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, t
Precision BioSciences announced its fourth quarter and fiscal year 2025 financial results, highlighting significant clinical advancements for its PBGENE-HBV and PBGENE-DMD programs. The company presented late-breaking data showing safety and antiviral activity from its Phase 1 ELIMINATE-B trial for chronic hepatitis B and received IND clearance for PBGENE-DMD, enabling further clinical trials. In a notable financial move, Precision raised $75 million to support its research pipeline through 2028, bolstering its position for potential key developments in the near future.
Read more →DTIL▼ -5.4%on this news· ran to +18% by day 3shared move
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program
Precision BioSciences has announced the receipt of two U.S. patent allowances for its PBGENE-HBV program. This development highlights the company's innovative ARCUS platform, which focuses on in vivo gene editing therapies for diseases with high unmet needs. The patents are expected to strengthen the company's position in the gene editing market.
Read more →DTIL▲ +13.6%on this newsshared move
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026
Precision BioSciences presented promising preclinical data on PBGENE-DMD at the Muscular Dystrophy Association Clinical & Scientific Conference 2026. The findings indicate durable dystrophin expression and functional improvements in muscle pathology in a humanized DMD mouse model. This innovative gene editing approach aims to enhance muscle function through satellite cell editing.
Read more →DTILPrecision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026
Precision BioSciences, a clinical stage gene editing company, has announced that it will report its fourth quarter and fiscal year 2025 results on March 12, 2026. The company utilizes its proprietary ARCUS platform to develop in vivo gene editing therapies aimed at addressing high unmet medical needs. This financial update is anticipated by stakeholders.
Read more →DTILPrecision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event
Precision BioSciences has received FDA Fast Track designation for PBGENE-DMD, aimed at treating Duchenne muscular dystrophy (DMD). This designation is a significant regulatory milestone that underscores the urgent need for new treatment options. The company will host a virtual investor event on March 17, 2026, to discuss the therapy and its planned Phase 1/2 FUNCTION-DMD clinical study.
Read more →DTILPrecision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
Precision BioSciences has received $7.5 million from TG Therapeutics due to a clinical milestone related to azer-cel, a treatment for progressive multiple sclerosis. The payment includes cash and stock purchases, reflecting TG Therapeutics' progress in the Phase 1 trial. This milestone underscores the potential of azer-cel and supports Precision's financial stability through 2028.
Read more →DTILPrecision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Precision BioSciences has announced its participation in the 2026 Muscular Dystrophy Association Clinical & Scientific Conference. The company will present new preclinical study data related to its ARCUS platform, which focuses on developing gene editing therapies for diseases with high unmet needs. This presentation underscores the company's commitment to advancing innovative treatments.
Read more →DTILPrecision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Precision BioSciences announced that new preclinical data for PBGENE-DMD will be presented at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference. The data suggests potential safety and long-term efficacy for this gene editing therapy aimed at treating Duchenne muscular dystrophy (DMD). The presentation is scheduled for March 9, 2026, in Orlando, Florida.
Read more →DTIL▲ +8.2%on this news
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy
Precision BioSciences has received FDA clearance to proceed with the FUNCTION-DMD Phase 1/2 clinical trial for PBGENE-DMD, a first-in-class gene editing therapy targeting Duchenne muscular dystrophy (DMD). This therapy aims to correct the dystrophin gene in patients with specific mutations, potentially benefiting a significant portion of the DMD population. The trial will assess safety, tolerability, and efficacy, with initial data expected by the end of 2026.
Read more →DTILPrecision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
Precision BioSciences has outlined its strategic priorities for 2026, focusing on advancing its clinical-stage programs, PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy. The ongoing Phase 1/2a ELIMINATE-B trial for PBGENE-HBV is set to provide data updates at medical conferences in 2026. Additionally, the company anticipates IND clearance for PBGENE-DMD in Q1 2026, with initial patient data expected later that year.
Read more →DTILPrecision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - December 23, 2025
Precision BioSciences, Inc. announced the approval of an inducement award of 8,224 restricted stock units to a new employee as part of its 2021 Employment Inducement Incentive Award Plan. This grant, approved by the Compensation Committee, is aimed at encouraging the new hire to join the company. The RSUs will vest annually over three years, contingent on continued service.
Read more →DTIL▼ -7.7%on this news
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025
Precision BioSciences has announced that it will present clinical data from the ELIMINATE-B trial at the HEP-DART 2025 conference. This presentation underscores the company's commitment to developing in vivo gene editing therapies for diseases with high unmet needs. The use of their proprietary ARCUS platform is a key aspect of their research efforts.
Read more →DTILPrecision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants
Precision BioSciences has announced a $75 million offering of common stock, pre-funded warrants, and warrants. This funding aims to support the company's operations and advance its gene editing therapies developed through its ARCUS® platform. The company is targeting high unmet need diseases, indicating a strong focus on innovation in the biopharma sector.
Read more →DTILPrecision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts
Precision BioSciences presented late-breaking data on PBGENE-HBV at AASLD, highlighting its safety and tolerability. The gene editing therapy showed cumulative, dose-dependent antiviral activity in the first three cohorts, indicating promising results in treating chronic Hepatitis B. This presentation marks a significant advancement in HBV treatment options.
Read more →DTILPrecision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update
Precision BioSciences reported its third quarter 2025 financial results, highlighting a late-breaking oral presentation at the Liver Meeting 2025. The presentation will showcase new data from various cohorts of the Phase 1 ELIMINATE-B trial for PBGENE-HBV in chronic hepatitis B. The company has also commenced dosing in Cohort 3, with further data expected in early 2026.
Read more →DTIL▼ -9.8%on this news· ran to -21% by day 3shared move
Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update - Late-breaking oral presentation at the Liver Meeting 2025 to feature new data from multiple cohorts of the Phase 1 ELIMINA
Precision BioSciences reported its third quarter 2025 financial results, highlighting progress in its gene editing pipeline. The company is conducting the Phase 1 ELIMINATE-B trial for PBGENE-HBV and recently initiated dosing in Cohort 3. Anticipated accomplishments include an IND filing for PBGENE-DMD by the end of 2025 and the start of its first-in-human trial expected in early 2026. The favorable safety and efficacy data positions the company well for future clinical milestones.
Read more →DTIL▼ -5.2%on this news· ran to -23% by day 3shared move
Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025
Precision BioSciences, a clinical-stage gene editing company, has announced that it will report its financial results for the third quarter of 2025 on November 3, 2025. The company utilizes its proprietary ARCUS platform to develop therapies aimed at diseases with high unmet needs. This announcement reflects the company's commitment to transparency and ongoing progress.
Read more →DTIL▲ +5.2%on this news· ran to +24% by day 3
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025
Precision BioSciences has announced its selection for a late-breaking oral presentation regarding PBGENE-HBV at AASLD The Liver Meeting 2025. This recognition underscores the company's innovative approach in gene editing therapies. The event is significant for showcasing advancements in treatments for high unmet need diseases.
Read more →DTILPrecision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases
Precision BioSciences has published findings in Nucleic Acids Research detailing the mechanisms behind the high efficiency of ARCUS nucleases in gene editing. The publication emphasizes the nucleases' capabilities for gene insertion, single base editing, and genomic DNA replacement. This research could significantly impact the field of genetic engineering.
Read more →DTILPrecision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial
Precision BioSciences has announced the opening of its first clinical trial site in the U.S. for the ELIMINATE-B trial, which focuses on chronic hepatitis B patients. The trial, designated as Phase 1 for PBGENE-HBV, is actively recruiting participants at Massachusetts General Hospital and is set to report additional data from higher dose cohorts in 2025.
Read more →DTIL▲ +8.4%on this news
Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society
Precision BioSciences announced a late-breaking poster presentation at the 30th Annual International Congress of the World Muscle Society. The presentation will showcase long-term preclinical efficacy and durability data for PBGENE-DMD, aimed at treating Duchenne Muscular Dystrophy. The company is on track to file an IND and/or CTA by the end of 2025, with clinical data expected in 2026.
Read more →DTIL▼ -7.8%on this news
Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium
Precision BioSciences presented data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium. The company highlighted the potential of its ARCUS platform in addressing significant unmet medical needs. The presentation marks a key milestone in their clinical development efforts.
Read more →DTILPrecision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status
Precision BioSciences has announced the granting of a U.S. patent for its PBGENE-HBV program, which targets chronic Hepatitis B and is protected until 2042. The Phase 1 ELIMINATE-B trial is currently progressing, with dosing for Cohort 3 set to begin in the third quarter of 2025. This development enhances the company's intellectual property and clinical advancement.
Read more →DTILPrecision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update
Precision BioSciences reported positive results from its Phase 1 ELIMINATE-B trial for PBGENE-HBV, aimed at treating Hepatitis B. The trial showed substantial antiviral activity in all patients of Cohort 1, with the best responses reaching 47-69%. Safety data for Cohort 2 was also announced, indicating ongoing progress in the trial.
Read more →DTILPrecision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update - Continued rapid progress with Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV for Hepatitis B Announced safety and effica
Precision BioSciences reported positive second quarter 2025 results, highlighting significant progress in their Phase 1 ELIMINATE-B trial for PBGENE-HBV, which showed promising antiviral activity and safety data. The company also received FDA designations for PBGENE-DMD, aimed at treating Duchenne Muscular Dystrophy, indicating a commitment to addressing unmet medical needs. Furthermore, with an extended cash runway into 2027, Precision is well-positioned for continued development and a planned Phase 2 study for PBGENE-HBV. Overall, the developments suggest a strong advancement in their therapeutic pipeline.
Read more →DTILPrecision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B - Proof-of-activity now established for PBGENE-HBV,
Precision BioSciences reported positive results from Cohort 1 of the Phase 1 ELIMINATE-B trial for PBGENE-HBV, targeting chronic Hepatitis B. The trial established proof-of-activity, indicating significant antiviral effects, with one patient showing a durable HBsAg reduction maintained over seven months. The drug was well-tolerated, and the company has plans to expand dosing in subsequent cohorts. However, two patients eventually returned to baseline HBsAg levels after initial reductions, highlighting ongoing challenges in achieving sustained therapeutic responses.
Read more →DTILPrecision BioSciences to Report Second Quarter 2025 Results on August 7, 2025
Precision BioSciences, a clinical stage gene editing company, has announced that it will report its second quarter 2025 results on August 7, 2025. The company utilizes its proprietary ARCUS platform to develop in vivo gene editing therapies aimed at addressing diseases with significant unmet medical needs. This report is anticipated to shed light on their advancements and future plans.
Read more →DTILPrecision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
Precision BioSciences has received FDA Orphan Drug Designation for its gene therapy PBGENE-DMD, aimed at treating Duchenne Muscular Dystrophy. This designation highlights the therapy's potential to address a critical unmet medical need. The company employs its proprietary ARCUS platform for developing in vivo gene editing therapies.
Read more →DTILPrecision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic
Precision BioSciences has announced promising new preclinical data for its PBGENE-DMD candidate, which shows an increase in dystrophin positive muscle cells across key muscle types. This data suggests that the gene editing approach may effectively target muscle satellite cells. The advancement supports the potential for clinical application in treating Duchenne Muscular Dystrophy.
Read more →DTIL▼ -7.2%on this news
Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
Precision BioSciences has received FDA Rare Pediatric Disease Designation for its gene therapy PBGENE-DMD, aimed at treating Duchenne Muscular Dystrophy. This designation underscores the therapy's potential to address a critical unmet need in pediatric patients. The company utilizes its proprietary ARCUS platform for developing innovative gene editing solutions.
Read more →DTIL▼ -8.1%on this news
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
Precision BioSciences reported its first quarter 2025 financial results, highlighting new clinical data for two programs that utilize ARCUS technology. The company presented initial safety data from the ongoing Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV at the EASL conference. The results validate the safety and efficacy of their in vivo gene editing approach.
Read more →DTIL▼ -8.1%on this newsshared move
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - Announced new clinical data for two programs utilizing ARCUS validating safety and efficacy for Precision's in vivo gene e
Precision BioSciences released its Q1 2025 financial results, announcing significant advancements in its clinical programs using the ARCUS gene editing platform. Initial safety data for the PBGENE-HBV trial was presented at the EASL Congress, showing promising results. The company also accelerated its PBGENE-DMD program, targeting an IND filing for 2025. With regulatory support from the FDA and MHRA, Precision is well-positioned to provide innovative treatments for chronic Hepatitis B and Duchenne's muscular dystrophy.
Read more →DTIL▼ -8.1%on this newsshared move
Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Precision BioSciences is advancing its PBGENE-DMD gene editing therapy aimed at Duchenne Muscular Dystrophy patients with specific dystrophin mutations. The therapy has shown compelling preclinical evidence, which was highlighted at the ASGCT Annual Meeting. This development marks a significant step in the company's organic pipeline.
Read more →DTILAll forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether
Precision BioSciences is advancing its PBGENE-DMD program for Duchenne Muscular Dystrophy, highlighting its compelling preclinical results at ASGCT 2025. The company aims to submit an Investigational New Drug application in 2025 with expectations for clinical data in 2026. PBGENE-DMD targets dystrophin mutations between exons 45-55 to potentially restore muscle function in patients. Current therapies for DMD do not provide significant improvement, making PBGENE-DMD a key development in addressing this severe condition.
Read more →DTILPrecision BioSciences to Report First Quarter 2025 Results on May 15, 2025
Precision BioSciences, a clinical stage gene editing company, announced it will report its first quarter 2025 results on May 15, 2025. The company utilizes its proprietary ARCUS platform to develop in vivo gene editing therapies aimed at addressing diseases with significant unmet medical needs. This report is anticipated to shed light on their advancements and future directions.
Read more →DTILPrecision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)
Precision BioSciences announced the presentation of initial safety data from its Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV at the upcoming EASL Congress. The data suggests positive outcomes for the gene editing therapy aimed at addressing hepatitis B. This presentation underscores the potential of Precision's ARCUS platform in treating diseases with significant unmet needs.
Read more →DTILPrecision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Precision BioSciences has announced multiple presentations regarding its in vivo gene editing programs at the ASGCT Annual Meeting. The company is leveraging its proprietary ARCUS platform to develop therapies focused on gene elimination, insertion, and excision. This participation highlights the company's commitment to advancing gene editing technologies.
Read more →DTIL▲ +23.8%on this news
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
Precision BioSciences has received Fast Track Designation from the U.S. FDA for its innovative gene editing therapy, PBGENE-HBV, aimed at treating chronic Hepatitis B. This designation is significant as it may expedite the development and review process due to the therapy's potential to address a major health concern. The company utilizes its proprietary ARCUS platform for this advancement.
Read more →DTIL▼ -5.9%on this news
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
Precision BioSciences, a clinical stage gene editing company, will participate in the 24th Annual Needham Virtual Healthcare Conference. The company utilizes its proprietary ARCUS platform to develop various in vivo gene editing therapies, including gene elimination, insertion, and excision programs. This participation underscores the company's commitment to advancing gene editing technologies.
Read more →DTIL▼ -11%on this news
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update
Precision BioSciences has reported its fourth quarter and fiscal year 2024 financial results, highlighting significant advancements in its gene editing programs. Notably, the company announced the first in vivo clinical validation for its ARCUS gene editing technology across two programs. Additionally, the Phase 1 ELIMINATE-B clinical trial for PBGENE-HBV has commenced, marking a milestone in Hepatitis B treatment.
Read more →DTIL▼ -11%on this newsshared move
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update • Announced first in vivo clinical validation for ARCUS gene editing across two distinct programs in
Precision BioSciences, Inc. has announced its financial results for Q4 and FY 2024, highlighting significant advancements in its ARCUS gene editing platform. Key milestones include the first in vivo clinical validation for ARCUS technology across two programs and the commencement of the Phase 1 ELIMINATE-B trial for PBGENE-HBV, targeted at chronic Hepatitis B. The company's early clinical data showed promising safety and antiviral activity, and it has secured necessary regulatory approvals to expand trials globally. Looking ahead, Precision aims to build upon this momentum with continued clinical execution and updates throughout 2025.
Read more →DTILPrecision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025
Precision BioSciences, a clinical stage gene editing company, is set to report its fourth quarter and fiscal year 2024 results on March 26, 2025. The company is known for its proprietary ARCUS platform, which focuses on developing in vivo gene editing therapies. Investors and stakeholders are keenly awaiting the results to assess the company's progress and future direction.
Read more →DTIL▲ +7%on this newsshared move
Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025
Precision BioSciences has presented promising preclinical safety and efficacy data for PBGENE-HBV, the first clinical stage gene editing therapy targeting chronic hepatitis B. The data supports the safety of repeat dosing, which is crucial for its therapeutic potential. The ELIMINATE-B global Phase 1 study is currently enrolling patients to further evaluate this innovative treatment.
Read more →DTILPrecision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Precision BioSciences presented promising preclinical data on PBGENE-DMD, a gene editing approach aimed at correcting the dystrophin gene for Duchenne Muscular Dystrophy (DMD). The treatment has the potential to benefit approximately 60% of DMD patients. Results indicated successful restoration of dystrophin protein expression and notable improvements in muscle function.
Read more →DTILPrecision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B
Precision BioSciences has received clearance from the U.S. FDA for its investigational gene editing therapy, PBGENE-HBV, aimed at treating chronic hepatitis B. This marks a significant regulatory achievement as it is the first in vivo gene editing therapy to enter clinical trials for this condition. The company plans to expand its Phase 1 clinical trials following this clearance.
Read more →DTILPrecision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Precision BioSciences announced its participation in the 2025 Muscular Dystrophy Association Clinical & Scientific Conference. The company focuses on in vivo gene editing therapies using its proprietary ARCUS platform. This presentation highlights their ongoing commitment to advancing gene editing technologies.
Read more →DTIL▲ +9.7%on this newsshared move
Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial
Precision BioSciences has reported initial safety and antiviral activity results for PBGENE-HBV in the ELIMINATE-B Phase 1 clinical trial. The trial is progressing as planned, with the first dose administered to three patients in cohort 1. The gene editing technology was found to be safe and well tolerated, showing promising antiviral effects against chronic Hepatitis B.
Read more →DTILPrecision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs
Precision BioSciences has announced key promotions within its leadership team, including Cindy Atwell as Chief Development and Business Officer and Cassie Gorsuch, PhD, as Chief Scientific Officer. These changes aim to bolster the company's efforts in advancing multiple in vivo gene editing programs. The leadership enhancements reflect Precision's commitment to innovation and growth in the gene editing sector.
Read more →DTIL▲ +26.7%on this news
Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
Precision BioSciences reported a complete clinical response in the first infant treated with ECUR-506 in an ongoing Phase 1/2 trial for Ornithine Transcarbamylase (OTC) deficiency. The treatment showed positive outcomes from three months post-exposure to the end of the six-month study period. Additionally, ECUR-506 was well tolerated, with no significant safety issues noted.
Read more →DTIL▼ -7.2%on this news
Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B
Precision BioSciences has received approval in Hong Kong to expand its PBGENE-HBV Phase 1 ELIMINATE-B trial, marking a significant milestone as it is the first in vivo gene editing clinical trial for chronic hepatitis B in the region. This approval is the second clinical trial application for PBGENE-HBV in 2024, and the study is currently recruiting patients globally.
Read more →DTIL▲ +11.7%on this news
Precision BioSciences to Participate in Upcoming November Investor Conferences
Precision BioSciences, a clinical stage gene editing company, announced its participation in upcoming investor conferences in November 2024. The company is known for its proprietary ARCUS® platform, which focuses on developing in vivo gene editing therapies. This engagement reflects the company's commitment to transparency and investor relations.
Read more →DTIL▲ +11.7%on this newsshared move
Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
Precision BioSciences has announced promising preclinical data for PBGENE-HBV, which indicates a strong safety profile and the potential to provide a functional cure for chronic hepatitis B. This data supports the progression into a first-in-human clinical trial, named ELIMINATE-B, which will evaluate the safety and efficacy of the treatment.
Read more →DTIL▲ +11.7%on this newsshared move
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Precision BioSciences has reported its third quarter 2024 financial results, highlighting the approval of its first Clinical Trial Application for PBGENE-HBV. This marks a significant step towards initiating first-in-human trials for chronic hepatitis B treatment. The phase 1 clinical program has commenced in Moldova, with patient screening currently in progress.
Read more →DTIL▲ +11.7%on this newsshared move
Precision BioSciences to Report Third Quarter Results on November 4, 2024
Precision BioSciences, Inc. has announced the date for its third quarter financial results, which will be published on November 4, 2024. The company focuses on developing in vivo gene editing therapies using its proprietary ARCUS platform. This announcement signals ongoing progress in their clinical stage initiatives.
Read more →DTIL▲ +11.7%on this newsshared move
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
Precision BioSciences will host a virtual investor event on November 15, 2024, to discuss the preclinical safety data of its PBGENE-HBV program and plans for a Phase 1 clinical trial. The event aims to highlight the company's innovative ARCUS platform for gene editing therapies targeting Hepatitis B. This initiative reflects the company's commitment to advancing its gene editing capabilities.
Read more →DTIL▲ +11.7%on this newsshared move
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
Precision BioSciences presented preclinical data at the ESGCT 31st Annual Congress, showcasing the capabilities of the ARCUS gene editing platform. The ARCUS approach utilizes homology-directed repair (HDR) to achieve high-efficiency gene editing, potentially allowing for a wider range of therapeutic applications compared to existing methods. This technology could be particularly beneficial for diseases requiring a gain in function.
Read more →DTIL▲ +11.7%on this newsshared move
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B
Precision BioSciences has received its first approval for a clinical trial application for PBGENE-HBV in Moldova, marking a significant step for its in vivo gene editing program targeting chronic hepatitis B. Additional regulatory applications are still pending. The company will also host an investor event to highlight the safety of its clinical candidate.
Read more →DTIL▲ +11.7%on this newsshared move
Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences
Precision BioSciences, a clinical stage gene editing company, has announced its participation in the upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences. The company utilizes its proprietary ARCUS platform to develop in vivo gene editing therapies. This involvement underscores its active role in the industry and commitment to advancing gene editing technologies.
Read more →DTIL▲ +11.7%on this newsshared move
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress
Precision BioSciences, Inc. will present at the 31st Annual Congress of the European Society of Gene & Cell Therapy. The company is known for its proprietary ARCUS platform, which is designed for advanced gene editing therapies, including gene insertion. This presentation highlights the company's commitment to innovative gene editing solutions.
Read more →DTIL▼ -8.1%on this news
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update - Received approval for first Clinical Trial Application to advance PBGENE-HBV into first-in-human trials for treatment of c
Precision BioSciences reported its third-quarter financial results and provided a business update, highlighting the approval for the first Clinical Trial Application for its PBGENE-HBV program aimed at treating chronic hepatitis B. The phase 1 clinical program has been opened in Moldova with patient screening currently in progress. Significant cash reserves are expected to enable ongoing development through 2026, with data from the PBGENE-HBV program anticipated throughout 2025. The company is actively preparing for a virtual investor event to discuss clinical plans in more detail.
Read more →DTILPrecision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B - Clinical Trial Application accepted in Moldova with addit
Precision BioSciences has received Clinical Trial Application approval in Moldova for its PBGENE-HBV treatment aimed at chronic hepatitis B. This marks the first in vivo gene editing program to enter clinical trials for this condition. The company is preparing to dose patients in its Phase 1 clinical study while pursuing additional global regulatory approvals. PBGENE-HBV aims to eliminate cccDNA, providing a potential functional cure for the 300 million people affected by chronic hepatitis B worldwide.
Read more →DTILPrecision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
Precision BioSciences, Inc. has announced its participation in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference. The company focuses on advanced gene editing using its proprietary ARCUS platform, which aims to develop therapies for complex gene edits, including the elimination of viral genes. This presentation underscores their commitment to innovation in gene therapy.
Read more →DTILPrecision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B
Precision BioSciences has submitted its first clinical trial applications to initiate a Phase 1 trial for PBGENE-HBV, a novel gene editing treatment for chronic hepatitis B. This drug modality aims to target the root cause of the disease by eliminating cccDNA and inactivating integrated HBV. The submission marks a significant step in advancing this innovative approach.
Read more →DTILPrecision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution
Precision BioSciences has announced key leadership changes, appointing Murray Abramson as Senior Vice President and Head of Clinical Development, and John Fry as Strategic Clinical Advisor for Hepatitis. Additionally, Alan List will retire as Chief Medical Officer but will continue as a Clinical Consultant on the Scientific Advisory Board. These changes aim to bolster the company's clinical execution for PBGENE-HBV.
Read more →DTILownership of our common stock, including fluctuations in our stock price; our ability to meet the requirements of and maintain listing of our common stock on Nasdaq or other public stock exchanges; and other important fa
Precision BioSciences has announced key leadership changes to bolster its clinical development team ahead of the anticipated PBGENE-HBV program. Dr. Murray Abramson has been appointed as Senior Vice President, while John Fry will serve as a Strategic Clinical Advisor specializing in hepatitis. With these appointments, the company aims to enhance its capabilities in moving forward with the PBGENE-HBV program and achieving important milestones by 2025. Alan List, the current Chief Medical Officer, will retire but will continue in a strategic advisory role.
Read more →DTILPrecision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference
Precision BioSciences, Inc. (Nasdaq: DTIL) will participate in the H.C. Wainwright 26th Annual Global Healthcare Conference. The company focuses on advanced gene editing using its proprietary ARCUS platform, which enables sophisticated gene edits. This participation highlights the company's commitment to advancing gene editing therapies.
Read more →DTILPrecision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal
Precision BioSciences has successfully received $13 million from the maturity of a convertible note with Imugene. This payment consists of $9.75 million in cash and $3.25 million in ordinary shares. The additional funds are expected to enhance Precision's cash runway, extending it into the latter half of 2026.
Read more →DTILPrecision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal -- Payment includes $9.75 million cash and $3.25 million in Imugene Limited ordinary
Precision BioSciences announced the maturity of a $13 million convertible note from its strategic partnership with Imugene, which includes both cash and ordinary shares. This financial boost is expected to extend the company's cash runway into the second half of 2026 and supports ongoing clinical development. The CEO highlighted the progress of azer-cel in oncology while indicating plans to file regulatory applications for PBGENE-HBV within the current year. This development reflects Precision's strategic focus on in vivo gene editing therapies.
Read more →DTILPrecision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis
Precision BioSciences has announced that its partner, TG Therapeutics, has received Investigational New Drug (IND) clearance from the U.S. FDA for azer-cel, an allogeneic CAR T therapy. This marks a significant step forward in the investigation of azer-cel for treating multiple sclerosis. The approval underscores the potential of Precision's ARCUS® platform in developing gene editing therapies.
Read more →DTILPrecision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
Precision BioSciences reported its second quarter 2024 financial results, highlighting progress in its wholly owned programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-PMM for mitochondrial disease. Both programs are on schedule for IND and CTA submissions in 2024 and 2025, respectively. The company also expanded its Hepatitis Scientific Advisory Board with renowned clinical investigators.
Read more →DTILPrecision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update - Wholly owned programs PBGENE-HBV for Chronic Hepatitis B virus and PBGENE-PMM for m.3243 mitochondrial disease on track f
Precision BioSciences reported strong progress in its second quarter 2024 results, highlighting advancements in their wholly owned gene editing programs, especially PBGENE-HBV for chronic Hepatitis B, which is set for IND submission. The company is well-capitalized to support ongoing and upcoming clinical trials, with expected cash runway extending into late 2026. Additionally, Precision regained control of key preclinical programs previously developed in collaboration with Prevail Therapeutics, further enhancing their development pipeline. The addition of notable clinical figures to their advisory board represents a significant step in bolstering their scientific collaboration efforts.
Read more →DTILPrecision BioSciences to Participate in Upcoming August Investor Conferences
Precision BioSciences, a gene editing company, announced its participation in upcoming investor conferences. The company is known for its proprietary ARCUS platform, which is focused on developing in vivo gene editing therapies. These therapies aim to achieve sophisticated gene edits such as elimination, insertion, and excision.
Read more →DTILPrecision BioSciences to Report Second Quarter Results on August 1, 2024
Precision BioSciences, a gene editing firm, will release its financial results for Q2 2024 on August 1, 2024. The company utilizes its proprietary ARCUS platform for developing in vivo gene editing therapies. This announcement reflects the company's ongoing commitment to transparency and innovation in the biopharma sector.
Read more →DTILPrecision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit
Precision BioSciences, a gene editing company, will present at the JonesTrading Healthcare Seaside Summit. This event highlights their proprietary ARCUS platform, which is focused on developing in vivo gene editing therapies. The presentation aims to enhance the company's visibility in the healthcare sector.
Read more →DTILPrecision BioSciences Announces its Addition to the Russell Microcap® Index
Precision BioSciences, Inc. has announced its inclusion in the Russell Microcap® Index. This recognition highlights the company's advancements in gene editing technology, particularly through its proprietary ARCUS® platform. The firm focuses on developing innovative in vivo gene editing therapies that encompass various sophisticated gene edits.
Read more →DTILPrecision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
Precision BioSciences announced a presentation at the UMDF Mitochondrial Medicine 2024 conference. The presentation will support the advancement of their PBGENE-PMM program towards an Investigational New Drug (IND) application and/or Clinical Trial Application (CTA) in 2025. This marks a significant step in their gene editing therapy development.
Read more →DTILPrecision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
Precision BioSciences has announced the expansion of its Hepatitis Scientific Advisory Board with the addition of Dr. Mark Sulkowski and Dr. Jordan Feld. This move comes as the company approaches clinical readiness for its PBGENE-HBV program, which aims to utilize its proprietary ARCUS platform for gene editing therapies. The inclusion of these world-class clinical investigators is expected to enhance the program's development.
Read more →DTILPrecision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
Precision BioSciences presented new preclinical safety data for PBGENE-HBV at the European Association for the Study of the Liver Congress. The data indicates that PBGENE-HBV effectively cuts HBV DNA without affecting the human genome. It was well tolerated in multiple administrations, showing no off-target editing, which supports its advancement to clinical trials as a potential curative treatment.
Read more →DTILPrecision BioSciences to Participate in Upcoming June Investor Conferences
Precision BioSciences, Inc. will participate in upcoming investor conferences in June 2024. The company is known for its innovative ARCUS platform, which enables sophisticated gene editing therapies, including gene elimination, insertion, and excision. This participation highlights the company's commitment to advancing its gene editing technologies.
Read more →DTIL▲ +8.1%on this news
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
Precision BioSciences has reported its first quarter 2024 financial results, highlighting that its wholly owned programs are on track for Clinical Trial Application (CTA) and Investigational New Drug (IND) submissions. The PBGENE-HBV program targeting Hepatitis B is expected to submit in 2024, while PBGENE-PMM for primary mitochondrial myopathy is anticipated in 2025. Additionally, the first ARCUS in vivo gene editing program has opened for enrollment in the UK.
Read more →DTIL▲ +8.1%on this newsshared move
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update - Wholly owned programs on track for CTA and/or IND submissions - PBGENE-HBV for Hepatitis B virus in 2024 and PBGENE-PMM fo
Precision BioSciences reported its first quarter financial results for 2024, highlighting significant progress across its gene editing programs. The company is on track for IND submissions for PBGENE-HBV aimed at treating Hepatitis B and plans to submit an IND for PBGENE-PMM by 2025. Additionally, they opened enrollment for their first ARCUS in vivo gene editing program in the UK and successfully monetized CAR T assets, enhancing their financial stability. However, the reassessment of advanced preclinical programs could present challenges for resource allocation.
Read more →DTIL▲ +6.6%on this newsshared move
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
Precision BioSciences, Inc. has announced a private placement of common stock, with management members purchasing shares worth $300,000. This investment is seen as a positive signal of confidence in the company's prospects. The funds will support the development of their ARCUS platform for gene editing therapies.
Read more →DTIL▲ +6.6%on this newsshared move
Precision BioSciences to Report First Quarter Results on May 13, 2024
Precision BioSciences, Inc. will report its first quarter results on May 13, 2024. The company is known for its innovative gene editing technologies, particularly its proprietary ARCUS platform. This platform is designed for in vivo gene editing therapies, enabling complex gene modifications such as elimination, insertion, and excision.
Read more →DTILPrecision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
Precision BioSciences has announced that its ECUR-506 program has received FDA Fast Track Designation. This designation is aimed at expediting the development of therapies for Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency. The company utilizes its proprietary ARCUS platform for advanced gene editing therapies.
Read more →DTILPrecision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
Precision BioSciences is set to present late-breaking data at the EASL Congress 2024. The presentation will focus on the latest preclinical safety data for PBGENE-HBV, which is crucial for upcoming regulatory filings. This highlights the company's commitment to advancing its gene editing platform.
Read more →DTIL▼ -10.6%on this news· ran to -25% by day 3
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
Precision BioSciences has announced the conclusion of its collaboration with Prevail Therapeutics, during which three programs were advanced and proof of concept for the ARCUS technology was demonstrated. The company has exercised its option to regain control of these programs and plans to develop them independently or with new partners.
Read more →DTILPrecision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics - Productive collaboration advanced three programs and demonstrated proof of concept of ARCUS for gene excision
Precision BioSciences has announced the return of three gene editing programs from Prevail Therapeutics after a productive collaboration that began in January 2021. The decision to regain control of these programs allows Precision to pursue independent development or new partnerships, particularly for its ARCUS gene editing platform. Notably, the company reported compelling proof-of-concept data for its gene excision and insertion therapies, enhancing the potential for broader therapeutic applications. The return of these programs does not impact Precision's ongoing clinical priorities, including studies related to Hepatitis B and Primary Mitochondrial Myopathy, and the company expects its cash runway to extend into the second half of 2026.
Read more →DTILPrecision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
Precision BioSciences has reported its fourth quarter and fiscal year 2023 financial results. The company has initiated final studies for its lead in vivo gene editing program, PBGENE-HBV, and anticipates submitting an IND and/or CTA in 2024. Additionally, Precision has completed licensing agreements to monetize its divested CAR T assets, generating nearly $50 million in upfront payments.
Read more →DTILPrecision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update - Initiated final IND/CTA enabling studies for lead in vivo gene editing program PBGENE-HBV; expect to subm
Precision BioSciences reported its financial results for Q4 and FY 2023, announcing significant advancements in its gene editing pipelines. The company initiated final studies for its lead program, PBGENE-HBV, and expects to submit IND and/or CTA in 2024. Additionally, Precision completed a $40 million public offering, which is anticipated to support its clinical objectives. The presentation of preclinical data for both PBGENE-HBV and PBGENE-PMM indicates strong efficacy and safety, marking a transformative year for the company.
Read more →DTILPrecision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
Precision BioSciences, Inc. is set to announce its fourth quarter and fiscal year 2023 results on March 27, 2024. The company specializes in advanced gene editing using its proprietary ARCUS platform. This announcement indicates ongoing progress in their gene editing therapies, which include various sophisticated gene edits.
Read more →DTILPrecision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
Precision BioSciences presented promising preclinical data for PBGENE-PMM at the Mitochondrial Medicine Therapeutic Development conference. The data showcased the ARCUS technology's capability to effectively eliminate mutant mitochondrial DNA without affecting nuclear DNA. This advancement could provide a new therapeutic option for patients with Primary Mitochondrial Myopathy.
Read more →DTILPrecision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
Precision BioSciences has received approval from the MHRA for its partner iECURE to expand the Phase 1/2 clinical trial of the ARCUS gene editing program targeting OTC deficiency. This approval is significant as it may lead to the insertion of a functional OTC gene, potentially offering lasting clinical benefits for affected children. The regulatory support enhances the prospects for effective treatments in this area.
Read more →DTIL▼ -31.2%on this newsshared move
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants DURHAM, N.C.
Precision BioSciences, Inc. announced a successful underwritten offering of 2,500,000 shares of common stock and accompanying warrants to purchase additional shares for a total of $40 million. The offering is priced at $16.00 per share and has garnered interest from notable life sciences investors. Proceeds from the offering are earmarked for ongoing research and development as well as general corporate purposes. The offering is expected to close on or around March 5, 2024.
Read more →DTIL▼ -31.2%on this newsshared move
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants
Precision BioSciences has announced a proposed public offering of common stock and warrants. This initiative aims to bolster its financial resources to further develop its gene editing therapies. The company focuses on sophisticated gene edits using its proprietary ARCUS platform, which includes gene insertion and excision capabilities.
Read more →DTIL▲ +5.6%on this news
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences
Precision BioSciences has entered into a non-exclusive patent license agreement with Caribou Biosciences. This collaboration aims to leverage Precision's ARCUS platform for developing advanced gene editing therapies. The agreement is expected to enhance the capabilities of both companies in the field of gene editing.
Read more →DTIL▲ +7.3%on this newsshared move
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness
Precision BioSciences has received pre-IND feedback from the U.S. FDA for its PBGENE-HBV program, indicating alignment with regulatory expectations. The company is currently conducting IND/CTA enabling studies and expects to file for IND and/or CTA in 2024. This program aims to be the first and only of its kind.
Read more →DTILPrecision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations
Precision BioSciences has promoted Naresh Tanna to Vice President of Investor Relations. This new senior-level position aims to enhance and expand the company's existing strategic investor relations program. The move reflects the company's commitment to strengthening its engagement with investors and stakeholders.
Read more →DTILPrecision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
Precision BioSciences has secured an initial cash payment of $7.5 million and an equity investment from TG Therapeutics. This funding is aimed at advancing the development of Azel-Cel, a treatment for autoimmune diseases. The collaboration leverages Precision's ARCUS platform for gene editing therapies.
Read more →DTILPrecision BioSciences to Effect a Reverse Stock Split
Precision BioSciences, Inc. announced a reverse stock split as part of its strategy to enhance stock performance. The company is known for its innovative ARCUS platform, which focuses on developing in vivo gene editing therapies. This move is aimed at improving the company's market position and shareholder value.
Read more →DTIL▲ +10.1%on this news
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
Precision BioSciences has finalized a licensing agreement with TG Therapeutics for its cell therapy, Azer-Cel, aimed at treating autoimmune diseases. The deal includes an upfront payment of $17.5 million and potential milestone payments totaling up to $288 million. This financial influx is expected to extend Precision's cash runway into the first half of 2026, supporting its ongoing projects.
Read more →DTIL▲ +10.1%on this newsshared move
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases - Precision to Receive $17.5 Million in Upfront and Near-Term Payments with Potential for up
Precision BioSciences has completed a license agreement with TG Therapeutics for the development of Azer-Cel, a cell therapy for autoimmune diseases. Precision will receive $17.5 million in initial payments and has the potential to earn up to $288 million in milestone payments. The partnership allows Precision to focus on its in vivo gene editing programs while leveraging TG's experience in immunology. The deal is expected to enhance Precision's financial stability into 2026 and supports ongoing development efforts.
Read more →DTILPrecision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE
Precision BioSciences has received approval from the Australian Therapeutic Goods Administration for its ECUR-506 gene insertion program. This marks the first clinical trial application for the ARCUS gene insertion program, developed in partnership with iECURE. The Phase 1/2 study aims to address OTC deficiency, highlighting the potential for innovative gene therapies.
Read more →DTILEfficient elimination of MELAS-associated m.3243G mutant mitochondrial DNA by an engineered mitoARCUS nuclease
The study presents the development of a mitoARCUS nuclease that effectively targets and eliminates the m.3243G mutant mitochondrial DNA associated with MELAS. This engineered nuclease demonstrated high specificity, preserving wild-type mtDNA while significantly improving mitochondrial function and respiration in a xenograft mouse model. The findings support its potential as a therapeutic approach for m.3243G-associated diseases.
Read more →DTIL▲ +5.8%on this news
Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases
Precision BioSciences has announced a publication in Nature Metabolism that supports the use of its ARCUS gene editing technology as a potentially curative treatment for mitochondrial diseases. The study highlights ARCUS's ability to specifically target and eliminate mutant m.3243G mitochondrial DNA, demonstrating efficient shifting of heteroplasmy without off-target effects. This advancement could significantly impact treatment options for patients with mitochondrial disorders.
Read more →DTIL▼ -10%on this newsshared move
Precision BioSciences to Present at Hep-DART 2023
Precision BioSciences, Inc. will present at Hep-DART 2023, showcasing its innovative ARCUS® platform. This platform is designed for in vivo gene editing therapies, enabling sophisticated gene edits such as insertion, excision, and elimination. The presentation highlights the company's advancements in gene editing technology.
Read more →DTILPrecision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences, Inc. has announced the grant of an inducement award under Nasdaq Listing Rule 5635(c)(4). This award supports the company's efforts in advancing its proprietary ARCUS platform for in vivo gene editing therapies. The announcement highlights the company's commitment to sophisticated gene edits, including insertion, excision, and elimination.
Read more →DTIL▼ -9.5%on this news
Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023
Precision BioSciences presented late-breaking data on PBGENE-HBV at AASLD's The Liver Meeting 2023. The data showcases the preclinical efficacy and safety of PBGENE-HBV, which is designed to eliminate cccDNA and inactivate HBV DNA. Notably, the candidate achieved up to 99% viral engagement without off-target editing. The final clinical candidate is now ready for CTA and/or IND submission.
Read more →DTILPrecision BioSciences to Present at Upcoming Sidoti Conference
Precision BioSciences, Inc. will present at the Sidoti Conference, showcasing its advanced gene editing capabilities. The company employs its proprietary ARCUS platform to develop in vivo gene editing therapies. This presentation highlights the company's commitment to sophisticated gene edits, including insertion, excision, and elimination.
Read more →DTILPrecision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Precision BioSciences has announced a late-breaking poster presentation at the AASLD Annual Meeting. The presentation will showcase their proprietary ARCUS platform, which is focused on in vivo gene editing. A webcast and conference call are scheduled for November 13, 2023, to discuss the details further.
Read more →DTILPrecision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update
Precision BioSciences has reported its third quarter 2023 financial results, showcasing advancements in its gene editing pipeline. The company is set to present late breaker data for PBGENE-HBV at The Liver Meeting in November 2023. Additionally, they have expanded their portfolio with PBGENE-PMM, aimed at treating m.3243 associated primary mitochondrial disease.
Read more →DTILPrecision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update - Precision to present late breaker PBGENE-HBV data at The Liver Meeting of AASLD in November 2023 - Hosted R&D Day highligh
Precision BioSciences reported its third-quarter 2023 financial results, highlighting a strategic focus on its ARCUS in vivo gene editing platform. The company plans to present late-breaking data for its PBGENE-HBV program at the upcoming AASLD meeting and has expanded its portfolio with PBGENE-PMM for mitochondrial myopathy. Additionally, a partnership with Imugene for a CAR T program has provided significant cash and equity while extending the company's financial runway through 2025. The aim is to advance their innovative gene editing therapies into clinical trials over the next few years.
Read more →DTIL▲ +29.6%on this news
Precision BioSciences to Report Third Quarter Results on November 7, 2023
Precision BioSciences, Inc. is scheduled to report its third quarter results on November 7, 2023. The company focuses on advanced gene editing using its proprietary ARCUS platform, which allows for sophisticated gene edits such as insertion, excision, and elimination. This announcement highlights the company's ongoing development in the field of gene therapies.
Read more →DTILPrecision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
Precision BioSciences presented preclinical data at the ESGCT 30th Annual Congress, showcasing the capabilities of its ARCUS technology for gene insertion and excision. The data highlighted ARCUS's high-efficiency gene insertion in non-human primates and its ability to achieve large gene excisions, resulting in significant muscle improvement in a Duchenne Muscular Dystrophy mouse model.
Read more →DTILPrecision BioSciences to Present at Upcoming H.C. Wainwright 4th Annual Hepatitis B Virus Conference
Precision BioSciences, Inc. will present at the H.C. Wainwright 4th Annual Hepatitis B Virus Conference. The company is known for its advanced gene editing capabilities using the ARCUS platform, which allows for sophisticated gene edits. This presentation is an opportunity to highlight their innovative approaches in gene therapy.
Read more →DTILPrecision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
Precision BioSciences, Inc. is set to present at the 30th Annual Congress of the European Society of Gene & Cell Therapy. The company leverages its proprietary ARCUS platform for advanced gene editing therapies, including gene insertion and elimination. This presentation highlights its commitment to innovative gene therapy solutions.
Read more →DTILPrecision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases
Precision BioSciences has received a U.S. patent allowance for its PBGENE-PMM product, aimed at treating m.3243-associated mitochondrial diseases. This development highlights the company's innovative use of its proprietary ARCUS platform for advanced gene editing therapies. The patent is a significant milestone for Precision BioSciences as it continues to advance its therapeutic offerings.
Read more →DTILPrecision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments
Precision BioSciences hosted a Virtual R&D Day to present new preclinical data related to its in vivo gene editing programs. The event emphasized the company's proprietary ARCUS technology and introduced PBGENE-PMM, a potential treatment for primary mitochondrial myopathy. Key opinion leaders participated in the event, discussing the advancements and future directions of the company's portfolio.
Read more →DTILPrecision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments - Company highlights new preclinical data for wholly-owned and partnered prog
Precision BioSciences hosted a virtual R&D Day to showcase its ARCUS technology and discuss advancements in its gene editing programs. Key updates included the unveiling of PBGENE-PMM, aimed at treating primary mitochondrial myopathy, and ongoing efforts to advance PBGENE-HBV for hepatitis B—a clinical trial application is anticipated by 2024. The event featured insights from notable experts and outlined the company's strategy to enhance its gene editing portfolio.
Read more →DTIL▼ -6.4%on this news
Precision BioSciences to Attend and Present at Upcoming September Investor Conferences
Precision BioSciences, Inc. (DTIL) has announced its participation in upcoming investor conferences. The company's management will present insights into its proprietary ARCUS platform, which focuses on in vivo gene editing therapies. This engagement reflects the company's commitment to fostering investor relations and showcasing its innovative technologies.
Read more →DTIL▼ -5.9%on this newsshared move
Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023
Precision BioSciences, a leader in gene editing, will host an R&D Day focused on in vivo gene editing therapies. The event is set for September 12, 2023, from 9:00 to 11:30 AM ET. This initiative highlights the company's ongoing research efforts and aims to foster collaboration within the industry.
Read more →DTILPrecision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer
Precision BioSciences has completed a strategic transaction with Imugene regarding Azer-Cel, which is aimed at treating LBCL patients. Under the agreement, Precision is eligible to receive up to $227 million in upfront payments and milestones, alongside double-digit royalties on sales. Imugene will manage Precision's cell therapy infrastructure as they work towards a Biologics License Application.
Read more →DTILPrecision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer - Precision Eligible to Receive up to $227 Million in Upfront Economics and Milestone Payments for Azer-Cel in Addition to Double-
Precision BioSciences has completed a strategic transaction with Imugene for global rights to Azer-Cel, their lead CAR T candidate targeting large B-cell lymphoma. Under the agreement, Imugene will assume control for clinical execution while Precision is set to receive up to $227 million, including cash, equity, and milestone payments. This partnership is expected to extend Precision's cash runway to Q3 2025 and allows the company to concentrate on in vivo gene editing. Imugene plans to leverage Azer-Cel's clinical data to advance its development into pivotal trials.
Read more →DTILPrecision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update
Precision BioSciences reported its second quarter 2023 financial results, highlighting positive FDA guidance for its lead CAR T program, Azer-Cel. The company is actively pursuing CAR T partnering discussions and presented encouraging preclinical data for its ARCUS technology in treating Duchenne Muscular Dystrophy and Chronic Hepatitis B. Additionally, they plan to host an In Vivo Gene presentation.
Read more →DTILPrecision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update - FDA Advice Provides Clarity on Future Development for Lead CAR T Program Candidate Azer-Cel; CAR T Partnering Discussions
Precision BioSciences reported its second quarter 2023 financial results, highlighting significant developments in its CAR T program azer-cel following FDA discussions. The company is focusing on its innovative ARCUS platform, with promising preclinical data for chronic Hepatitis B and ongoing partnerships for gene editing programs. Financially, Precision ended the quarter with approximately $137.8 million in cash, anticipated to sustain operations through the first quarter of 2025. Partnering discussions for CAR T therapies are progressing as the company seeks to solidify its market position.
Read more →DTIL▼ -5.3%on this newsshared move
Precision BioSciences to Report Second Quarter Results on August 4, 2023
Precision BioSciences, a clinical stage gene editing company, will release its financial results for the second quarter of 2023 on August 4, 2023. The company focuses on ARCUS-based in vivo gene editing and ex vivo allogeneic CAR T therapies. This announcement highlights the company's commitment to transparency and progress in its clinical developments.
Read more →DTILPrecision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day
Precision BioSciences has provided updates regarding its recent FDA Type B meeting, where it received final meeting minutes. The company is focused on its ARCUS-based in vivo gene editing and ex vivo CAR T therapies. Additionally, it is exploring potential partnerships to support its research and development efforts.
Read more →DTIL▼ -11.9%on this news
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward Azer-Cel Safety Profile was Significantly Improved Compared to Prior Cohorts in Patients Dosed Using Optimized Product at Low
Precision BioSciences announced significant updates regarding its allogeneic CAR T programs, focusing on two candidates: Azer-cel and PBCAR19B. Azer-cel demonstrated an 83% overall response rate and a 61% complete response rate in a cohort of CAR T relapsed patients, with an acceptable safety profile. Additionally, PBCAR19B achieved a 71% overall response rate and 80% in DLBCL patients, suggesting a potential for further development. The company plans to align with the FDA on a potential Phase 2 study for Azer-cel, furthering its advancement in CAR T therapies.
Read more →DTILPrecision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update - Program Updates Planned for Azer-cel and PBCAR19B in May 2023 - Presented data on PBGENE-HBV program at Global Hepatitis S
Precision BioSciences reported its financial results for Q1 2023, indicating revenue growth driven by its partnership with Novartis. The company plans to update on its azer-cel and PBCAR19B CAR T programs in May 2023 and showcased supportive data from its PBGENE-HBV program at the Global Hepatitis Summit. Furthermore, Precision’s strong cash position is expected to fund operations through Q1 2025, even as research and development expenses rise.
Read more →DTIL▲ +10.1%on this news
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26 th Annual Meeting - Presentation to Hig
Precision BioSciences has announced a late-breaking abstract showcasing preclinical data from its PBGENE-DMD program, aimed at treating Duchenne muscular dystrophy (DMD). This abstract has been selected for oral presentation at the American Society of Gene & Cell Therapy's 26th Annual Meeting, set to take place from May 16-20, 2023, in Los Angeles. The research highlights the use of ARCUS nucleases to excise a significant mutation from the dystrophin gene, potentially leading to viable treatments for DMD. The abstract will be accessible online prior to the event, demonstrating the company's commitment to advancing gene editing therapies.
Read more →DTIL▼ -11.3%on this news· ran to -23% by day 3
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update - Advanced ARCUS Gene Editing Development for Clinical and Research Programs; In Vivo Gene Editing R&D Day
Precision BioSciences announced fourth quarter and fiscal year 2022 financial results, highlighting advancements in ARCUS gene editing technology and allogeneic CAR T therapies. The company reported increased revenues, with a cash balance that supports operations through Q1 2025. Positive feedback was received from the FDA regarding the azer-cel process, and significant upcoming data presentations are expected for multiple programs in 2023. Precision continues to explore partnerships and enhance their clinical pipelines.
Read more →DTILPrecision BioSciences Announces Senior Leadership Promotions and Organizational Changes - Neil Leatherbury Appointed Senior Vice President, Head of CMC – - Derek Jantz, Ph.D., to Assume Advisory Position of Co-Fou
Precision BioSciences has announced key promotions and organizational changes among its senior leadership team, with Neil Leatherbury appointed as Senior Vice President, Head of CMC. Derek Jantz, Ph.D., transitions to an advisory role after significant contributions since the company's founding. Co-founder Jeff Smith continues to lead research strategy while overseeing new collaborative efforts. The leadership changes aim to strengthen the company's potential for advancing ARCUS-based therapies and progressing towards commercialization in 2023.
Read more →DTIL▼ -8.1%on this news
Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones DURHAM, N.C.—(BUSINESS WIRE)—
Precision BioSciences reviewed its accomplishments from 2022 and outlined plans for 2023, focusing on its gene editing therapies. Key achievements from 2022 include successful collaborations with Novartis and robust clinical results for its lead CAR T therapy, azer-cel. The company anticipates major milestones, including progressing to Phase 2 trials and regulatory submissions for its in vivo gene editing programs. Additionally, Precision plans to continue prioritizing its research pipeline to address pressing unmet medical needs.
Read more →DTILPrecision BioSciences Announces Change to its Board of Directors - Raymond F. Schinazi, Ph.D., to Step Down from Board of Directors and Continue as a Member of the Company's Scientific Advisory Board (SAB) DURHAM, N.C.
Precision BioSciences Announces Change to its Board of Directors -Raymond F. Schinazi, Ph.D., to Step Down from Board of Directors and Continue as a Member of the Company's Scientific Advisory Board (SAB) DURHAM, N.C.-- Nov. 10, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL)
Read more →DTILPrecision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update - Allogeneic CAR T Program Updates Planned for Late Q4 2022 or Early Q1 2023 - Abstract Showcasing Functional Attributes of
Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update -Allogeneic CAR T Program Updates Planned for Late Q4 2022 or Early Q1 2023 -Abstract Showcasing Functional Attributes of Azer-cel (PBCAR1091) Accepted for Presentation at the 64th A
Read more →DTILthose expenses will be; Precision's limited operating history; the success of its programs and product candidates in which it expends its resources; Precision's limited ability or inability to assess the safety and effic
Precision BioSciences Announces Senior Leadership Organizational Changes DURHAM, N.C. Sep 2, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS -based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announ
Read more →DTIL▼ -7.5%on this news
Precision BioSciences Reports Second Quarter 2022 Financial Results and Provides Business Update - Launched Exclusive In Vivo Gene Insertion Collaboration with Novartis to Develop Single ARCUS Nuclease as Potential One-t
Precision BioSciences Reports Second Quarter 2022 Financial Results and Provides Business Update DURHAM, N.C., August 8, 2022 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS -based ex vivo allogeneic CAR T and in vivo gene ed
Read more →DTIL▲ +7.2%on this news· ran to +27% by day 3
Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease - Precision to Receive $75 Million Upfront for a Sing
Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease DURHAM, N.C.-June 21, 2022 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company
Read more →DTIL▲ +10.3%on this newsshared move
Precision BioSciences Announces $50 Million Offering of Common Stock DURHAM, N.C.
Precision BioSciences Announces $50 Million Offering of Common Stock DURHAM, N.C.-June 21, 2022 - Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced
Read more →DTIL▼ -12.9%on this news· ran to -42% by day 3
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population PBCAR0191 Achieved 100% Response Rate (ORR), 73% Complete Respon
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population PBCAR0191 Achieved 100% Response Rate (ORR), 73% Complete Response (CR) Rate and 50% Durable Response Greater than Six Mont
Read more →DTILPrecision BioSciences Appoints Melinda Brown to Board of Directors New Director Brings Proven Financial and Leadership Experience Fifth Director Added to the Board of Directors Since April 2021 DURHAM, N.C.
Precision BioSciences Appoints Melinda Brown to Board of Directors New Director Brings Proven Financial and Leadership Experience Fifth Director Added to the Board of Directors Since April 2021 DURHAM, N.C., May 31, 2022 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinica
Read more →DTIL▼ -9.8%on this news· ran to -22% by day 3
Precision BioSciences Reports First Quarter 2022 Financial Results and Provides Business Update - PBCAR0191, PBCAR19B and PBCAR269A Allogeneic CAR T Program Updates Planned for June 2022 - Three Wholly Owned In Vivo Gene
Precision BioSciences Reports First Quarter 2022 Financial Results and Provides Business Update DURHAM, N.C., May 9, 2022 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS -based ex vivo allogeneic CAR T and in vivo gene editin
Read more →DTIL▼ -16.4%on this news
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update - Advancing ARCUS Platform by Developing In Vivo Gene Editing Programs for Genetic Diseases and Ex Vivo CAR
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update DURHAM, N.C., March 15, 2022 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS -based ex vivo allogeneic CAR T and
Read more →DTILPrecision BioSciences to Present at the 40 th Annual J.P. Morgan Health Care Conference DURHAM, N.C.
Precision BioSciences to Present at the 40th Annual J.P. Morgan Health Care Conference DURHAM, N.C., January 4, 2022 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its
Read more →DTILgreenhouse studies and clinical or field trials; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, biotechnology and agricultural biotechnology
Precision BioSciences Completes Spin-Out of Elo Life Systems DURHAM, N.C., December 21, 2021 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS genome editing pl
Read more →DTILPrecision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update - Appointed Michael Amoroso as President and Chief Executive Officer and to Board of Directors; Sam Wadsworth, Ph.D., and Sh
Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update DURHAM, N.C., November 10, 2021 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS genome editing platform to develop allogeneic CAR
Read more →DTILPrecision BioSciences Appoints Sam Wadsworth, Ph.D. and Shari Lisa Pir , J.D. to Board of Directors New Directors Add Decades of Cell and Gene Therapy Development and Strategic Business Growth Experience DURHAM, N.C.--(B
Precision BioSciences Appoints Sam Wadsworth, Ph.D. and Shari Lisa Pir , J.D. to Board of Directors New Directors Add Decades of Cell and Gene Therapy Development and Strategic Business Growth Experience DURHAM, N.C.--(BUSINESS WIRE)-November 8, 2021-- Precision BioSciences, In
Read more →DTILPrecision BioSciences to Present at the Jefferies Virtual Gene Therapy/Editing Summit on Thursday
Precision BioSciences to Present at the Jefferies Virtual Gene Therapy/Editing Summit on Thursday, October 27, 2021 DURHAM, N.C.-October 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS genome editing platform to deve
Read more →DTILPrecision BioSciences Appoints Michael Amoroso Chief Executive Officer DURHAM, N.C.
Precision BioSciences Appoints Michael Amoroso Chief Executive Officer DURHAM, N.C., September 27, 2021 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS genome editing platform to develop allogeneic CAR T and in vivo gene edit
Read more →DTILInvestor Contact: Alex Kelly Chief Financial Officer Alex.Kelly@precisionbiosciences.com Media Contact: Maurissa Messier Senior Director, Corporate Communications Maurissa.Messier@precisionbiosciences.com
Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline DURHAM, N.C., September 9, 2021 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies
Read more →DTILPrecision BioSciences Reports Second Quarter 2021 Financial Results and Provides Business Update - Presented Interim Data Showing PBCAR0191 with Enhanced Lymphodepletion Yielded Overall Response Rate of 75% and Complete
Precision BioSciences Reports Second Quarter 2021 Financial Results and Provides Business Update Response Rate of 75% and Complete Response Rate of 50% at Day 28 DURHAM, N.C., August 12, 2021 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company
Read more →DTILCertain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential CONSULTING AGREEMENT This CONSULTING AGREEMENT
Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential CONSULTING AGREEMENT This CONSULTING AGREEMENT ("Agreement") is made by and between Precision BioScience
Read more →DTILPrecision BioSciences Reports Progress on Two Strategies Designed to Optimize Durability of Allogeneic CAR T Therapy in R/R Non-Hodgkin Lymphoma Company Reports Updated Phase 1/2a Interim Study Results for 12 R/R Non-Hod
Precision BioSciences Reports Progress on Two Strategies Designed to Optimize Durability of Allogeneic CAR T Therapy in R/R Non-Hodgkin Lymphoma Company Reports Updated Phase 1/2a Interim Study Results for 12 R/R Non-Hodgkin Lymphoma Patients who Received PBCAR0191 CAR T Cells F
Read more →DTILSenior Director, Corporate Communications maurissa.messier@precisionbiosciences.com
Precision BioSciences Appoints Alex Kelly as Chief Financial Officer DURHAM, N.C., May 27, 2021 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS genome editing p
Read more →DTILPrecision BioSciences Reports First Quarter and 2021 Financial Results and Provides Business Update - Reacquired Global Development and Commercialization Rights to all Servier Partnered CAR T Programs, Including PBCAR019
Precision BioSciences Reports First Quarter and 2021 Financial Results and Provides Business Update - Reacquired Global Development and Commercialization Rights to all Servier Partnered CAR T Programs, Including PBCAR0191 and PBCAR19B Stealth Cell - Expect to Present Updated PB
Read more →DTILPrecision BioSciences Reacquires Global Rights to its Allogeneic CAR T Programs - Precision Reacquires from Servier its Global Development and Commercialization Rights and Control of All Partnered CAR T Programs, Includi
Precision BioSciences Reacquires Global Rights to its Allogeneic CAR T Programs - Precision Reacquires from Servier its Global Development and Commercialization Rights and Control of All Partnered CAR T Programs, Including PBCAR0191 and PBCAR19B Stealth Cell - Servier Eligible
Read more →DTILpublic perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, biotechnology and agricultural biotechnology fields; our or our collaborators' ability to iden
Precision BioSciences Appoints Renowned Hematologist Alan List, M.D. as Chief Medical Officer DURHAM, N.C., April 15, 2021 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with
Read more →DTILPrecision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update Established in vivo genome editing research collaboration and exclusive license agreement with Eli Lilly Re
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update Established in vivo genome editing research collaboration and exclusive license agreement with Eli Lilly Reported interim data from Phase 1/2a study of PBCAR0191; up
Read more →DTILPrecision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol Levels in Nonhuman Primates Study Led by Gene Therapy Program at the Univ
Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol Levels in Nonhuman Primates Study Led by Gene Therapy Program at the University of Pennsylvania Published in Molecular Therapy DURH
Read more →DTILPrecision BioSciences Receives Notice of Allowance for U.S. Patent Application Covering PBCAR19B, a Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma DURHAM, N.C.
Precision BioSciences Receives Notice of Allowance for U.S. Patent Application Covering PBCAR19B, a Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma DURHAM, N.C., January 25, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical sta
Read more →DTILPrecision BioSciences Announces Executive Leadership Change DURHAM, N.C.
Precision BioSciences Announces Executive Leadership Change DURHAM, N.C., December 14, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS genome editing platf
Read more →DTILPrecision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL) Acceptable Tolerability a
Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL) Acceptable Tolerability and Safety Profile in 27 Patients with No Graft versus Host
Read more →DTILPrecision BioSciences Reports Third Quarter 2020 Financial Results and Provides Business Update Expanded allogeneic CAR T development collaboration with Servier to include four new programs targeting hematological and so
Precision BioSciences Reports Third Quarter 2020 Financial Results and Provides Business Update Expanded allogeneic CAR T development collaboration with Servier to include four new programs targeting hematological and solid tumors Advanced CAR T clinical pipeline, including a c
Read more →DTILconditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking stateme
Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma Increasing BCMA Surface Expression and Reduced Soluble BCMA Levels with Gamma Secret
Read more →DTILPrecision BioSciences and Servier Expand CAR T Oncology Development Collaboration with Four New Programs Targeting Hematological and Solid Tumors DURHAM, N.C. and PARIS, France
Precision BioSciences and Servier Expand CAR T Oncology Development Collaboration with Four New Programs Targeting Hematological and Solid Tumors DURHAM, N.C. and PARIS, France -- September 17, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage
Read more →DTILPrecision BioSciences Reports Second Quarter 2020 Financial Results and Provides Business Update Dosed First Patient in Phase 1/2a Clinical Trial of PBCAR269A, a BCMA-Targeted Allogeneic CAR T Candidate for Multiple Myel
Precision BioSciences Reports Second Quarter 2020 Financial Results and Provides Business Update Dosed First Patient in Phase 1/2a Clinical Trial of PBCAR269A, a BCMA-Targeted Allogeneic CAR T Candidate for Multiple Myeloma PBCAR0191 and PBCAR20A Clinical Studies Progressing; U
Read more →DTILPrecision BioSciences Regains Rights to In Vivo Hepatitis B Virus Program DURHAM, N.C.
Precision BioSciences Regains Rights to In Vivo Hepatitis B Virus Program DURHAM, N.C., July 6, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS genome edi
Read more →DTILThis presentation (together with any other statements or information that we may make in connection herewith) may contain forward-looking statements. All statements other than statements of present and historical facts c
June 2020 Exhibit 99.1 This presentation (together with any other statements or information that we may make in connection herewith) may contain forward-looking statements. All statements other than statements of present and historical facts contained in this prospectus, includi
Read more →DTILPrecision BioSciences Reports First Quarter 2020 Financial Results and Provides Business Update Dosed First Patient in Phase 1/2a Clinical Study of PBCAR20A in Relapsed/Refractory NHL, CLL, and SLL PBCAR0191 Phase 1/2a T
Precision BioSciences Reports First Quarter 2020 Financial Results and Provides Business Update Dosed First Patient in Phase 1/2a Clinical Study of PBCAR20A in Relapsed/Refractory NHL, CLL, and SLL PBCAR0191 Phase 1/2a Trial is Progressing with Updated Interim Data Expected in
Read more →DTILPrecision BioSciences Strengthens Board of Directors with Appointment of Geno Germano Durham, N.C.
Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germano Durham, N.C., March 11, 2020 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS geno
Read more →DTILPrecision BioSciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update -Presented initial clinical data for lead allogeneic CAR T program PBCAR0191 for the treatment of NHL and B
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update -Presented initial clinical data for lead allogeneic CAR T program PBCAR0191 for the treatment of NHL and B-ALL- -Implemented amendment to PBCAR0191 Phase 1/2a trial
Read more →DTILdtil-ex991_6.pptx.htm 38th Annual J.P. Morgan Healthcare Conference
38th Annual J.P. Morgan Healthcare Conference January 15, 2020 This presentation (together with any other statements or information that we may make in connection herewith) may contain forward-looking statements. All statements other than statements of present and historical fac
Read more →DTILPrecision BioSciences Welcomes Healthcare Industry Expert, Kevin J. Buehler, to its Board of Directors Durham, N.C.
Precision BioSciences Welcomes Healthcare Industry Expert, Kevin J. Buehler, to its Board of Directors Durham, N.C., November 13, 2019 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, p
Read more →DTILPrecision BioSciences Reports Third Quarter 2019 Financial Results and Highlights Ongoing Operational Progress Including Initial Data from PBCAR0191 Phase 1/2a Clinical Trial Durham, N.C.
Precision BioSciences Reports Third Quarter 2019 Financial Results and Highlights Ongoing Operational Progress Including Initial Data from PBCAR0191 Phase 1/2a Clinical Trial Durham, N.C., November 12, 2019 - Precision BioSciences, Inc. (Nasdaq: DTIL) ("Precision"), a genome ed
Read more →DTILDedicated To Improving Life Overcome Cancer. Cure Genetic Disease. Feed the Planet. Delivering on the Promise of Genome Editing to Address Core Challenges of Human Health Proprietary ARCUS genome editing platform built f
Dedicated To Improving Life Overcome Cancer. Cure Genetic Disease. Feed the Planet. Delivering on the Promise of Genome Editing to Address Core Challenges of Human Health Proprietary ARCUS genome editing platform built for translation with full freedom to operate Industry leadin
Read more →DTILPrecision BioSciences Appoints David Thomson, PhD, as Chief Operating Officer Durham, N.C.
Precision BioSciences Appoints David Thomson, PhD, as Chief Operating Officer Durham, N.C., Sept. 23, 2019 - Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS platform, a
Read more →DTILPrecision BioSciences Reports Second Quarter 2019 Financial Results and Highlights Ongoing Operational Progress Durham, N.C.
Precision BioSciences Reports Second Quarter 2019 Financial Results and Highlights Ongoing Operational Progress Durham, N.C., August 14, 2019 - Precision BioSciences, Inc. (Nasdaq: DTIL) ("Precision"), a genome editing company dedicated to improving life through the application
Read more →DTILPrecision BioSciences Reports First Quarter 2019 Financial Results Durham, North Carolina
Precision BioSciences Reports First Quarter 2019 Financial Results Durham, North Carolina, April 29, 2019 - Precision BioSciences, a genome editing company dedicated to improving life (Nasdaq: DTIL) ("Precision") through the application of its proprietary ARCUS genome editing pl
Read more →Competitive Position
How DTIL ranks across every disease it competes inCompetitive Position is a premium feature
See how DTIL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial